biostudies-literatureUnknown19(7)Satoh TF. Hoffmann-La Roche Ltd<h4>Background</h4>The Trastuzumab for Gastric Cancer phase III trial demonstrated that combining trastuzumab with chemotherapy significantly improved overall survival compared with chemotherapy alone in HER2-positive advanced gastric or gastroesophageal junction cancer. We report health-related quality of life (HRQoL) and quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) results from this trial.<h4>Patients and methods</h4>Patients were randomized to receive six cycles of chemotherapy given every 3 weeks (capecitabine or fluorouracil, plus cisplatin) either alone or combined with administration of trastuzumab every 3 weeks until disease progression. At each clinical visit, HRQoL was assessed using two European Organization for Research and Treatment of Cancer qualityThe oncologist712-9https://www.ebi.ac.uk/biostudies/studies/S-EPMC4077451biostudies-literatureQuality of life in the trastuzumab for gastric cancer trial.PMC4077451Moiseyenko VMOhtsu AWeber HAGotovkin EAHamamoto YBang YJUrspruch AChung HCSatoh TVan Cutsem EToGA Trial InvestigatorsKang YKAl-Sakaff NHill JfalseQuality of life in the trastuzumab for gastric cancer trial.<h4>Background</h4>The Trastuzumab for Gastric Cancer phase III trial demonstrated that combining trastuzumab with chemotherapy significantly improved overall survival compared with chemotherapy alone in HER2-positive advanced gastric or gastroesophageal junction cancer. We report health-related quality of life (HRQoL) and quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) results from this trial.<h4>Patients and methods</h4>Patients were randomized to receive six cycles of chemotherapy given every 3 weeks (capecitabine or fluorouracil, plus cisplatin) either alone or combined with administration of trastuzumab every 3 weeks until disease progression. At each clinical visit, HRQoL was assessed using two European Organization for Research and Treatment of Cancer quality2014-01-01T00:00:00Z2014 Jul2026-05-03T23:23:25.827Z2019-03-27T01:31:13ZS-EPMC40774512495160910.1634/theoncologist.2014-0058